Regardless of ethnicity and PD-L1 expression, promising efficacy has been observed in heavily pretreated patients with NSCLC who received tislelizumab as monotherapy and in untreated patients with NSCLC who received tislelizumab in combination with chemotherapy (18). The gene discussed is CD274; the disease is non-small cell lung carcinoma.